Durvalumab extends survival in small cell lung cancer but raises cost concerns
A new study suggests that the immune checkpoint inhibitor, durvalumab, may offer new treatment options for patients living…
Inflammation and immune suppression fuel aggressive SCLC behavior and spread
Small cell lung cancer (SCLC) is one of the most aggressive forms of lung cancer, with a five-year…
Study finds a new protein target against KRAS-driven non-small cell lung cancer
Lung cancer is the second-most common cancer and the leading cause of cancer death in the United States.…
How COVID mRNA vaccines may make cancer treatments more effective
A new study reveals that SARS-CoV-2 mRNA vaccines can amplify immune checkpoint therapy in lung and skin cancers…
Adjuvant chemo-immunotherapy may benefit patients with resected stage IB–IIIA NSCLC, trial suggests
Interim results from the NADIM ADJUVANT Phase III trial, led by the Spanish Lung Cancer Group (GECP), suggest…